Expanding horizons in Parkinson’s disease care with non-pharmacological interventions

The field of non-pharmacological interventions for the treatment of individuals with Parkinson’s disease (PD) is reaching maturity and has the potential to substantially improve patient care in the future.

Xlife Sciences AG Announces the Intended Listing of VERAXA Biotech AG on the NASDAQ Stock Exchange in the 2025 Fiscal Year – Biotech Investments

Xlife Sciences AG / Key word(s): IPO/Market launch 16-Dec-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer

December 17, 2024

Canopy Growth Q2 Revenue Sinks as Losses Increase

Canopy Growth Reports Second Quarter Fiscal Year 2025 Financial Results Storz & Bickel net revenue increased 32% year-over-year in Q2 FY2025 Continued growth across medical

November 8, 2024

Crown jewel from AbbVie’s Cerevel buyout fails two Phase 2 schizophrenia tests, Bristol Myers’ stock soars

The centerpiece of AbbVie’s $8.7 billion Cerevel acquisition just imploded. Emraclidine, a schizophrenia program expected to compete with the newly-approved Cobenfy from Bristol Myers Squibb

November 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.